1.Pre-operative neoadjuvant chemotherapy: mainly systemic chemotherapy, if necessary, intra-arterial infusion chemotherapy, the main goal of diagnosis and treatment is to transform some “inoperable locally advanced breast cancer” into “operable breast cancer”. The main goal of the treatment is to convert some of the “inoperable advanced localized breast cancer” into “operable breast cancer”, and to convert some of the “non-breast-conserving locally advanced breast cancer” into “breast-conserving breast cancer”. 2. Postoperative adjuvant chemotherapy: At present, the indications for postoperative adjuvant chemotherapy are relatively wide, and adjuvant chemotherapy should be considered for patients with invasive cancer with the longest diameter greater than or equal to 1cm. At present, except for a few people who still use CMF, more adjuvant chemotherapy for breast cancer is based on anthracycline, and paclitaxel can be considered for those with positive lymph nodes and negative hormone receptors. The patient’s physical condition (cardiopulmonary function, liver and kidney function, etc.), postoperative pathology (pathological stage – especially tumor size, differentiation, presence or absence of cancer emboli, receptor status, Her-2 expression, Ki-67 expression), economic conditions and willingness for diagnosis and treatment should be taken into consideration, and if necessary, FISH or CISH examination and 21-gene testing should be considered to clarify molecular typing and guide further diagnosis and treatment. If necessary, FISH or CISH and 21-gene testing can be considered in combination to clarify molecular typing and guide further treatment. Endocrine therapy only should be considered for some ER and PR positive elderly patients. 3. Chemotherapy for advanced or recurrent metastatic breast cancer. As for chemotherapy for advanced, relapsed or metastatic breast cancer, it is generally considered and individualized according to the previous drug use. For those who have not used anthracyclines and paclitaxel drugs, anthracyclines and paclitaxel drugs should be considered first. Commonly used second-line drugs include vincristine, gemcitabine, capecitabine, platinum (cisplatin, carboplatin, etc.), etc. For some receptor-positive individuals, endocrine therapy may be considered.